Nrx pharmaceuticals, inc. (nasdaq:nrxp) announces completion of twelve months of stability on the first manufactured commercial scale lot of nrx-100 (ketamine)

Stability milestone supports submission of fda new drug application by nrx for the use of intravenous ketamine to treat suicidal depression ketamine is currently used off-label for this indication. however, fda approval is typically required for patients to obtain insurance reimbursement nrx-100 is the first preservative-free formulation of ketamine, potentially avoiding toxic side effects of preservatives used in current preparations designed for single dose anesthetic use radnor, pa.
NRXP Ratings Summary
NRXP Quant Ranking